| |
Title |
|
Last Modified |
Submitter |
Submission ID |
|
|
Warfarin Consortium Combined Data Set, March 2008 |
|
08/12/2008 |
IWPC
|
PS206767
|
|
|
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin |
|
08/12/2008 |
IWPC,
PBAT
|
PS207531
|
|
|
Bone mineral density in tamoxifen patients |
|
06/04/2008 |
COBRA
|
PS207749
|
|
|
Susceptibility Loci Involved in Cisplatin-Induced Apoptosis |
|
01/09/2008 |
PAAR
|
PS207138
|
|
|
Susceptibility Loci Involved in Cisplatin-Induced Cytotoxicity |
|
01/09/2008 |
PAAR
|
PS207139
|
|
|
Depression Scores in Mexican-Americans Treated with Fluoxetine or Desipramine - Terminated |
|
01/04/2008 |
PPRG
|
PS207299
|
|
|
Depression Scores in Mexican-Americans Treated with Fluoxetine or Desipramine - Dropouts |
|
01/04/2008 |
PPRG
|
PS207298
|
|
|
Depression Scores in Mexican-Americans Treated with Fluoxetine or Desipramine |
|
01/04/2008 |
PPRG
|
PS207297
|
|
|
WashU Pharmacogenetic Warfarin Dose Adjustment Phenotype Data |
|
10/07/2007 |
PBAT
|
PS206799
|
|
|
Mapping Genes that Contribute to Daunorubicin-Induced Cytotoxicity |
|
06/13/2007 |
PAAR
|
PS206924
|
|
|
Genetic Variants Contributing to Daunorubicin-Induced Cytotoxicity |
|
06/08/2007 |
PAAR
|
PS206925
|
|
|
Identification of Genetic Variants Contributing to Cisplatin-Induced Cytotoxicity using a Genome-wide Approach |
|
06/06/2007 |
PAAR
|
PS206923
|
|
|
Genetic variants associated with etoposide-induced cytotoxicity |
|
06/01/2007 |
PAAR
|
PS206922
|
|
|
SLC29A2 Functional Protein Variants |
|
01/18/2007 |
PMT
|
PS205403
|
|
|
SLC22A8 Functional Protein Variants |
|
01/15/2007 |
PMT
|
PS205427
|
|
|
RNA expression in metabolite and transport genes |
|
01/07/2007 |
CREATE
|
PS204378
|
|
|
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of CYP3A5 |
|
01/03/2007 |
PAAR
|
PS205161
|
|
|
Gene expression in ALL cells correlating with GSTM1 deletion germline genotype |
|
12/19/2006 |
PAAR
|
PS205024
|
|
|
Gene expression in ALL cell affected by UGT1A1*28 germline genotype |
|
12/19/2006 |
PAAR
|
PS205025
|
|
|
Genetic determinants of UGT1A1 inducibility by phenobarbital in hepatocytes |
|
11/09/2006 |
PAAR
|
PS205549
|
|
|
Heritability of sensitivity to cisplatin-induced cytotoxicity |
|
11/03/2006 |
PAAR
|
PS203969
|
|
|
AS3MT Functional Protein Variants, Comparative Genomics and Structural Implications |
|
11/01/2006 |
PPII
|
PS205575
|
|
|
MTHFR Functional Protein Variants, Comparative Genomics and Structural Implications |
|
11/01/2006 |
PPII
|
PS205574
|
|
|
FMO3 Regulatory Polymorphisms |
|
10/13/2006 |
PFMO
|
PS204686
|
|
|
SLC22A2 Functional Protein Variants |
|
10/09/2006 |
PMT
|
PS205430
|
|
|
Hepatic CYP3A4 mRNA expression (Cohort III) |
|
08/29/2006 |
PAAR
|
PS205553
|
|
|
G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. |
|
08/29/2006 |
PAAR
|
PS205694
|
|
|
Hepatic CYP3A5 predicts Saquinavir clearance |
|
08/29/2006 |
PAAR
|
PS205446
|
|
|
Intestinal CYP3A4 Protein Expression (Cohort IV) |
|
08/29/2006 |
PAAR
|
PS205555
|
|
|
Intestinal Midazolam Hydroxylase Activity (Cohort V) |
|
08/29/2006 |
PAAR
|
PS205554
|
|
|
Testosterone 6beta-hydroxylation Activity Induced by Rifampin (Cohort I) |
|
08/29/2006 |
PAAR
|
PS205551
|
|
|
Maximal CBR1 and NQO1 activities in liver cytosols |
|
08/29/2006 |
PAAR
|
PS205428
|
|
|
Identification of genes associated with chemotherapy cross-resistance and treatment response in childhood acute lymphoblastic leukemia |
|
08/29/2006 |
PAAR
|
PS205043
|
|
|
Folate pathway gene expression and methotrexate pharmacodynamics |
|
08/29/2006 |
PAAR
|
PS204895
|
|
|
Cross resistance to prednisolone, asparaginase, vincristine and daunorubicin in ALL cells |
|
08/29/2006 |
PAAR
|
PS205041
|
|
|
Gene expression profiling of ALL cells resistant to asparaginase or vincristine |
|
08/29/2006 |
PAAR
|
PS205042
|
|
|
Lymphoid gene expression as a predictor of risk of radiation-induced secondary brain tumors. |
|
08/29/2006 |
PAAR
|
PS204894
|
|
|
Hepatic CYP3A4 Protein Expression and Midazolam Hydroxylation (Cohort II) |
|
08/29/2006 |
PAAR
|
PS205552
|
|
|
A modulator of HERG Potassium Channel block |
|
03/22/2006 |
PAT
|
PS203999
|
|
|
Pharmacokinetics of Tamoxifen at 4 months |
|
02/27/2006 |
COBRA
|
PS204851
|
|
|
Drug-Induced Long QT Intervals |
|
02/27/2006 |
PAT
|
PS204823
|
|
|
Patient responses to tamoxifen - set 2 |
|
02/27/2006 |
COBRA
|
PS204128
|
|
|
Metabolism of yohimbine by human CYP450 isoforms |
|
02/27/2006 |
APP
|
PS203846
|
|
|
Characteristics of Variant Sodium Channels |
|
02/27/2006 |
PAT
|
PS203998
|
|
|
Outcomes in Asthmatics taking montelukast |
|
12/12/2005 |
PHAT-PAM
|
PS205464
|
|
|
Risk classfication of childhood ALL and TYMS, GSTM1 gene expression in ALL cells. |
|
11/07/2005 |
PAAR
|
PS205023
|
|
|
Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia |
|
11/07/2005 |
PAAR
|
PS204896
|
|
|
SLC28A1 Functional Protein Variants |
|
11/07/2005 |
PMT
|
PS204626
|
|
|
SLC18A2 Functional Protein Variants |
|
11/04/2005 |
PMT
|
PS204630
|
|
|
SLC15A2 Functional Protein Variants |
|
11/04/2005 |
PMT
|
PS204629
|
|
|
SLC22A6 Functional Protein Variants |
|
11/04/2005 |
PMT
|
PS204628
|
|
|
Bronchodilator response to beta agonist in asthmatics |
|
11/04/2005 |
BARGA
|
PS204055
|
|
|
Effects of Dapsone on CYP2C9 Variants and Naproxen Metabolism |
|
11/03/2005 |
CIA
|
PS204772
|
|
|
CYP2C9 Variants and Piroxicam Metabolism |
|
11/03/2005 |
CIA
|
PS204776
|
|
|
CYP2C9 Variants and Flurbiprofen Metabolism |
|
11/03/2005 |
CIA
|
PS204775
|
|
|
CYP2C9 Variants and Naproxen Metabolism |
|
11/03/2005 |
CIA
|
PS204774
|
|
|
Genetic Epidemiology of Responses to Antihypertensives (GERA) |
|
11/03/2005 |
GERA
|
PS204345
|
|
|
mRNA expression levels of PXR splice variants in livers |
|
09/30/2005 |
PAAR
|
PS204223
|
|
|
Survival of patients on beta-blockers after ACS, and ADRB1, ADRB2 |
|
09/27/2005 |
CREATE
|
PS205292
|
|
|
Pharmacokinetics of methotrexate in children with ALL |
|
06/13/2005 |
PAAR
|
PS203978
|
|
|
PAPSS2 Functional Protein Variants |
|
06/02/2005 |
PPII
|
PS203786
|
|
|
SULT1C1 functional protein variants |
|
06/02/2005 |
PPII
|
PS203789
|
|
|
SLC28A2 Functional Protein Variants |
|
06/02/2005 |
PMT
|
PS204625
|
|
|
SLC28A3 Functional Protein Variants |
|
06/02/2005 |
PMT
|
PS204627
|
|
|
SULT2A1 Functional Protein Variants |
|
06/02/2005 |
PPII
|
PS203791
|
|
|
Effects of Dapsone on CYP2C9 Variants and Flurbiprofen Metabolism |
|
06/02/2005 |
CIA
|
PS204773
|
|
|
Meperidine N-demethylation by human CYP450 isoforms |
|
06/02/2005 |
PAAR
|
PS203913
|
|
|
EGFR promoter activity in transfected cells -216G/T-191C/A |
|
06/02/2005 |
PAAR
|
PS204192
|
|
|
WUSTL warfarin dosing data, group A |
|
06/01/2005 |
PBAT
|
PS204852
|
|
|
Folate, Homocysteine and Vitamin B12 in Young Healthy Individuals |
|
03/09/2005 |
GOFMOP
|
PS204263
|
|
|
NAT2 Phenotype and Hypersensitivity to Sulfonamides |
|
01/25/2005 |
NATPG
|
PS204762
|
|
|
Drug Levels in Depressed Mexican-Americans |
|
12/15/2004 |
PPRG
|
PS203993
|
|
|
Development of treatment-related acute myeloid leukemia |
|
12/14/2004 |
PAAR
|
PS204268
|
|
|
Analysis of variation in mouse TPMT expression and activity. |
|
12/07/2004 |
CREATE
|
PS204377
|
|
|
Cytotoxicity of 5-fluorouracil in the CEPH population |
|
12/07/2004 |
CREATE
|
PS204376
|
|
|
Cytotoxicity of docetaxel in the CEPH population |
|